Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.48 is 82% above its 5-year average of -2.68, near the high end of its 5-year range (-4.88–-0.48).
41.82% above its 12-month average of -0.82.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.48
EARNINGS PER SHARE (EPS) AVG TTM
-0.82
EARNINGS PER SHARE (EPS) AVG 3Y
-2.37
EARNINGS PER SHARE (EPS) AVG 5Y
-2.68
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.82%
CURRENT VS 3Y AVG
+79.75%
CURRENT VS 5Y AVG
+82.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inhibikase Therapeutics, Inc.
Market Cap
$261.43M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
Market Cap
$261.27M
Earnings Per Share (EPS)
-1.20
TTM Avg
-3.73
3Y Avg
-17.53
5Y Avg
-47.09
Market Cap
$262.92M
Earnings Per Share (EPS)
-1.30
TTM Avg
-1.74
3Y Avg
-1.50
5Y Avg
-1.50
Market Cap
$259.56M
Earnings Per Share (EPS)
-0.69
TTM Avg
-0.60
3Y Avg
-0.18
5Y Avg
-0.21
Market Cap
$259.49M
Earnings Per Share (EPS)
-0.93
TTM Avg
-0.92
3Y Avg
-0.85
5Y Avg
-0.65
Market Cap
$259.14M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
Market Cap
$259.12M
Earnings Per Share (EPS)
-1.15
TTM Avg
-2.48
3Y Avg
-2.45
5Y Avg
-2.00
Market Cap
$258.63M
Earnings Per Share (EPS)
-0.53
TTM Avg
-5.25
3Y Avg
-13.51
5Y Avg
-397.38
Market Cap
$264.25M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $261.43M | -0.48 | -0.82 | -2.37 | -2.68 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -1.20 | -3.73 | -17.53 | -47.09 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -1.30 | -1.74 | -1.50 | -1.50 |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -0.69 | -0.60 | -0.18 | -0.21 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | -0.93 | -0.92 | -0.85 | -0.65 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | -0.99 | -0.90 | -0.84 | -0.86 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | -1.15 | -2.48 | -2.45 | -2.00 |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -0.53 | -5.25 | -13.51 | -397.38 |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -3.74 | -2.75 | -2.51 | -2.60 |
Trailing EPS (TTM)
$-0.48
Forward EPS (Est.)
$-0.45
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.49 |
| 2024-12-31 | -1.16 |
| 2023-12-31 | -3.57 |
| 2022-12-31 | -4.26 |
| 2021-12-31 | -4.88 |
| 2020-12-31 | -1.72 |
| 2019-12-31 | -3.34 |
| 2018-12-31 | -1.61 |
| 2017-12-31 | -0.25 |
| 2016-12-31 | -0.48 |
